公开(公告)号：US12202895B2

公开(公告)日：2025-01-21

申请号：US17275838

申请日：2019-09-12

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM ,  IMMUNE-ONC THERAPEUTICS, INC.

Inventor： Zhiqiang An ,  Chengcheng Zhang ,  Ningyan Zhang ,  Xun Gui ,  Mi Deng ,  Tao Huang ,  Qiang Liu ,  X. Charlene Liao

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  A61K47/68 ,  A61K47/69 ,  A61K51/10 ,  A61P35/02 ,  G01N33/574

Abstract: The present disclosure provides an isolated monoclonal antibody or an antigen-binding fragment thereof that binds specifically to leukocyte immunoglobulin-like receptor 4 (LILRB4). In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, modulates the activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, activates LILRB4. In certain embodiments, the antibody or antigen binding fragment, when bound to LILRB4, suppresses activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, specifically blocks binding of ApoE to LILRB4. In another aspect, there is provided a method of treating or ameliorating the effects of a cancer in a subject, comprising administering to the subject a therapeutically effective amount of the antibody or an antigen-binding fragment thereof or an engineered cell as provided herein.

公开(公告)号：US12161618B2

公开(公告)日：2024-12-10

申请号：US18093840

申请日：2023-01-06

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： James B. Brugarolas ,  Haley Hill ,  Tao Wang

IPC: A61K31/135 ,  A61K31/275 ,  A61P35/00 ,  G01N33/50 ,  A61K45/06

Abstract: The present disclosure provides methods of identifying patients who have partial or total resistance to HIF-2 inhibitors or who develop partial or total resistance to HIF-2 inhibitors after treatment and providing suitable treatment to these patients.

公开(公告)号：US20240398708A1

公开(公告)日：2024-12-05

申请号：US18540656

申请日：2023-12-14

Applicant: The Board of Regents of The University of Texas System

Inventor： Shao-Ling HUANG ,  Melvin E. KLEGERMAN ,  Yong-Jian GENG ,  Hyunggun KIM ,  David D. MCPHERSON

IPC: A61K9/127 ,  A61K9/00 ,  A61K33/00 ,  A61K41/00

Abstract: Methods for the treatment of stroke, such as stroke of undetermined origin, by administration of xenon (Xe)-loaded liposome compositions are provided. In some aspects, Xe is encapsulated in echogenic liposomes and release of Xe can be enhanced by application of ultrasound stimulation. Compositions for use in treating stroke, such as liposomes loaded with Xe or Xe in combination with H2 or H2S, are also provided.

公开(公告)号：US20240383999A1

公开(公告)日：2024-11-21

申请号：US17995214

申请日：2021-04-01

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Ningyan ZHANG ,  Zhiqiang AN ,  Zhiqiang KU ,  Hui DENG ,  Lingegowda S MANGALA ,  Anil K. SOOD

IPC: C07K16/28 ,  A61K39/00

Abstract: Provided herein are anti-CD5L monoclonal antibodies. Further provided herein are methods of use thereof for the treatment of a disease or disorder, such as cancer.

公开(公告)号：US20240376199A1

公开(公告)日：2024-11-14

申请号：US18691229

申请日：2022-09-13

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Zhiqiang AN ,  Ningyan ZHANG ,  Peng ZHAO

IPC: C07K16/28

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments etc., that specifically bind a TREM2 protein or a TREM2 protein epitope, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US12138479B2

公开(公告)日：2024-11-12

申请号：US17597509

申请日：2020-07-13

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Weiguo Lu ,  Xuejun Gu ,  Mingli Chen ,  Xun Jia ,  Steve Bin Jiang

IPC: A61N5/10

Abstract: The present disclosure is directed towards a treatment planning system for use in a stereotactic radiotherapy system. In particular, the disclosed systems and methods may be used for generating a treatment plan and/or verifying an existing treatment plan. Moreover, the disclosed systems and methods may be suitable for use in a clinical setting. A method for verifying a treatment plan of a stereotactic radiotherapy device may include the steps of receiving a treatment plan, generating a second treatment plan by applying a modified monte-carlo method to regions of interest in the treatment plan, and identifying discrepancies between the received treatment plan and the generated second treatment plan.

公开(公告)号：US12134609B2

公开(公告)日：2024-11-05

申请号：US18334325

申请日：2023-06-13

Applicant: IMMUNESENSOR THERAPEUTICS, INC. ,  THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Jian Qiu ,  Qi Wei ,  Matt Tschantz ,  Heping Shi ,  Youtong Wu ,  Huiling Tan ,  Lijun Sun ,  Chuo Chen ,  Zhijian Chen

IPC: C07D401/14 ,  C07D215/38 ,  C07D215/42 ,  C07D215/46 ,  C07D401/04 ,  C07D403/04 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/08 ,  C07D491/048 ,  C07F9/6503 ,  C07F9/6506

Abstract: The present disclosure provides compounds that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.

公开(公告)号：US20240344084A1

公开(公告)日：2024-10-17

申请号：US18603950

申请日：2024-03-13

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Berge A. MINASSIAN ,  Emrah GUMUSGOZ

IPC: C12N15/86 ,  C12N7/00

CPC classification number: C12N15/86 ,  C12N7/00 ,  C12N2750/14143 ,  C12N2750/14151

Abstract: The present disclosure provides methods and compositions for the treatment of diseases and genetic disorders linked to CSTB loss and/or misfunction. The methods and compositions of the present disclosure include rAAV vectors and rAAV viral vectors comprising transgene nucleic acid molecules encoding CSTB polypeptides.

公开(公告)号：US12116597B2

公开(公告)日：2024-10-15

申请号：US17824621

申请日：2022-05-25

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Dong H. Kim ,  Yanning Rui ,  Zhen Xu ,  John Hagan

IPC: C12N5/071 ,  A61B17/12 ,  A61K31/351 ,  A61K31/37 ,  A61K31/404 ,  A61K31/4706 ,  A61K31/496 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/517 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/55 ,  A61K38/10 ,  A61P9/00 ,  A61P9/10 ,  C07K14/495

CPC classification number: C12N5/069 ,  A61B17/1215 ,  A61K31/351 ,  A61K31/37 ,  A61K31/404 ,  A61K31/4706 ,  A61K31/496 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/517 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/55 ,  A61K38/10 ,  A61P9/00 ,  A61P9/10 ,  C07K14/495 ,  C12N2510/02

Abstract: Disclosed here are uses of autophagy inhibitors for treating a subject at risk of suffering from an aneurysm. The present disclosure demonstrates that autophagy plays a role in THSD1-mediated focal adhesion stability and aneurysm formation and characterizes molecular targets for therapeutic intervention.

公开(公告)号：US20240318198A1

公开(公告)日：2024-09-26

申请号：US18274485

申请日：2022-02-02

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Ryan BUTLER ,  Steven J. GRAY ,  Hye Ri KANG ,  Berge A. MINASSIAN ,  Emrah GUMUSGOZ

IPC: C12N15/86 ,  C12N15/113

CPC classification number: C12N15/86 ,  C12N15/113 ,  C12N2310/531 ,  C12N2750/14143

Abstract: The present disclosure provides methods and compositions for the treatment of Angelman Syndrome The methods and compositions of the present disclosure comprise isolated nucleic acid molecules, rAAV vectors and rAAV viral vectors comprising polynucleotide sequences encoding for short hairpin RNA (shRNA) molecules directed against UBE3A-ATS.